| bcl-2 |  |
Anti-bcl-2 has shown consistent negative reaction on reactive germinal centers and positive staining of neoplastic follicles in follicular lymphoma. Consequently, this antibody is valuable when distinguishing between reactive and neoplastic follicular proliferation in lymph node biopsies. This antibody may also be used in distinguishing between those follicular lymphomas that express bcl-2 protein and the small number in which the neoplastic cells are bcl-2 negative. Anti-bcl-2 has been used as a predictive biomarker for recurrence in the case of radical prostatectomy for prostate cancer, and has shown promise as a prognostic marker in the case of cancer of the breast and non-small cell carcinoma of the lung.
Mouse Monoclonal, Clone: 124| | 0.1 ml concentrated | 226M-94 | | | 0.5 ml concentrated | 226M-95 | | | 1 ml concentrated | 226M-96 | | | 1 ml prediluted | 226M-97 | | | 7 ml prediluted | 226M-98 | | | Ventana®* dispenser | 760-4240 | | | 5 Positive Control Slides | 226S | | |
|
Regulatory Status
|
Rabbit Monoclonal, Clone: E17| | 0.1 ml concentrated | 226R-14 | | | 0.5 ml concentrated | 226R-15 | | | 1 ml concentrated | 226R-16 | | | 1 ml prediluted | 226R-17 | | | 7 ml prediluted | 226R-18 | | | 5 Positive Control Slides | 226S | | | |
|
